YMTX Description — Kineta Inc
Yumanity Therapeutics is a biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. Co.'s primary program, YTX-7739, is in development for the potential treatment and disease modification of Parkinson's disease. YTX-7739 targets an enzyme known as stearoyl-CoA desaturase (SCD). Inhibition of SCD in multiple cellular systems, including patient-derived neurons, as well as in a mouse model of Parkinson's disease, has been demonstrated to reverse the toxicity of misfolded alpha-synuclein, a protein strongly associated with Parkinson's disease.
|
Free YMTX Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |